These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23699967)

  • 1. Dialysis facility profit status and compliance with a black box warning.
    Ishida JH; McCulloch CE; Dudley RA; Grimes BA; Johansen KL
    JAMA Intern Med; 2013 Jun; 173(12):1152-3. PubMed ID: 23699967
    [No Abstract]   [Full Text] [Related]  

  • 2. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
    Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
    Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to guidelines for ESRD anemia management.
    Hynes DM; Stroupe KT; Kaufman JS; Reda DJ; Peterman A; Browning MM; Huo Z; Sorbara D
    Am J Kidney Dis; 2006 Mar; 47(3):455-61. PubMed ID: 16490624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study.
    Monda KL; Joseph PN; Neumann PJ; Bradbury BD; Rubin RJ
    BMC Nephrol; 2015 May; 16():67. PubMed ID: 25928734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 12. Performance measures in dialysis facilities: what is the goal?
    Finkelstein FO
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):156-8. PubMed ID: 25189927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erythropoietin in renal anemia].
    Peña Amaro MP; García López J; Camacho Romera M
    Rev Enferm; 1992 Mar; 15(163):67-70. PubMed ID: 1565973
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythropoietin for chronic ambulatory peritoneal dialysis patients: once a week can be enough.
    Hood VL; Ingraham A
    J Am Soc Nephrol; 1992 Apr; 2(10):1545-6. PubMed ID: 1600126
    [No Abstract]   [Full Text] [Related]  

  • 15. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system.
    Robinson B; Fuller D; Zinsser D; Albert J; Gillespie B; Tentori F; Turenne M; Port F; Pisoni R
    Am J Kidney Dis; 2011 Jun; 57(6):822-31. PubMed ID: 21530036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
    Rodríguez Palomares JR; Fanlo B; Albarracín C; Junquera E
    Nefrologia; 2003; 23(2):181-2. PubMed ID: 12778887
    [No Abstract]   [Full Text] [Related]  

  • 17. Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin.
    McKoy JM; Tigue CC; Bennett CL
    Cancer Treat Res; 2008; 140():235-51. PubMed ID: 18283779
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
    Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
    BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 20. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
    Parker KP; Sands JM
    J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.